Back to results

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

Primary Purpose

Oral Lichen Planus

Status

Completed

Phase

Phase 2

Locations

Brazil

Study Type

Interventional

Intervention

Bifidobacterium animalis subsp. lactis HN019

Clobetasol propionate 0.05%

About this trial

This is an interventional treatment trial for Oral Lichen Planus focused on measuring Oral lichen planus, Probiotics, Immunomodulation.

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Clinical inclusion
- Adults ≥ 18 years old, both genres, who consent to participate of the study;
- Presence of symptomatic reticular lesion and/or white-gray papules. In afro-descendent individuals, reticular lesions may be associated with hyperpigmented lesions;
- Additional clinical features such as ulcerative, erythematous, plaque and bullous lesions will be accepted in the presence of bilateral and symmetrical reticular lesions.
Histopathological inclusion criteria
- Presence of subepithelial infiltrate predominantly lymphocytic, in band and confined to the subepithelial area.
- Liquefaction degeneration of the basal cells layer.

Exclusion Criteria:

Clinical exclusion criteria
- Exclusion of contact lichenoid lesions: the pattern of reticular lesion and / or papules should not be present only in areas of physical contact with restorative materials;
- Exclusion of lichenoid reaction to the drug: difficult to differentiate from OLP, however it is necessary to report all drugs in use by the patient; the comparison between patients on medication, and those who do not use medication is important to establish subgroups of OLP;
- Exclusion of chronic graft versus host disease (GVHD): differentiation between OLP and GVHD is established in most cases by medical history;
- Exclusion of immunocompromised patients or patients with systemic diseases of high complexity.
- Exclusion of patients who have previously used probiotic bacteria in the last 4 weeks prior to the study.
Histopathological criteria for exclusion • Presence of epithelial dysplasia, absence of the lymphocytic inflammatory infiltrate band and liquefaction degeneration.

Sites / Locations

School of Dentistry of Ribeirão Preto, University of São Paulo

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Bifidobacterium animalis subsp. lactis

Clobetasol propionate 0.05%

Arm Description

Intervention: Bifidobacterium animalis subsp. lactis HN019

Intervention: Clobetasol propionate 0.05%

Outcomes

Primary Outcome Measures

Change in symptoms intensity measure

Self reported symptoms at baseline, 15 and 30 days after therapy through an visual analogue scale (VAS). It consists of a subjective scale scoring the symptoms from 0 to 10 (0 = no symptoms and 10 = as bad as can be).

Secondary Outcome Measures

Histopathological analysis

Biopsies will be collected at the baseline stage or at the time of the diagnosis of OLP (optional), consisting of a 5mm x 5mm fragment or a 4mm punch of reticular lesions. The second biopsy will be optional, with patient consent, close to the area of the first biopsy for comparative purposes. The histological findings will be determined quantitatively and qualitatively regarding the presence of epithelial hyperplasia, degeneration by liquefaction of the basal cells layer, lymphocytic infiltrate in the subepithelial connective tissue, and apoptotic cells. Photographs will be used at 400x and quantification using the Image J. program.

Immunohistochemical analysis

The population of inflammatory cells will be characterized by analysis of oral mucosa samples, with emphasis on the T cell line (CD3, CD4, CD8, CD25, CD103, perforin, granzyme B and Foxp3), B cells (CD20 / CD20), dendritic cells (CD123 and CD303), submucosal dendritic cells (CD209 and factor XIIIa), Langerhans cells (CD1a and CD207), endothelial activity (e-selectin and CD31), mast cells ), macrophages (CD68 and CD163), myeloid dendritic cells (S100 and CD11c), cell proliferation markers (Ki-67, MCM-2, MCM-5, cyclin D1) and extracellular matrix (laminin-5). For immunohistochemical reactions, histological sections of 3μm thickness will be performed, which will be placed on slides coated with organosilane (Sigma-Aldrich, St Louis, MO, USA).

Venous blood collection

10 ml of venous blood to evaluate the probiotic systemic effect, by means of the research of pro-inflammatory, anti-inflammatory and regulatory cytokines.

Full Information

NCT ID

NCT03386643

First Posted

December 2, 2017

Last Updated

March 25, 2020

Sponsor

University of Sao Paulo

1. Study Identification

Unique Protocol Identification Number

NCT03386643

Brief Title

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

Official Title

Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus

Study Type

Interventional

2. Study Status

Record Verification Date

March 2020

Overall Recruitment Status

Completed

Study Start Date

November 6, 2017 (Actual)

Primary Completion Date

April 5, 2018 (Actual)

Study Completion Date

December 6, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

University of Sao Paulo

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Lichen planus is a chronic inflammatory mucocutaneous disease, which often results in oral manifestations, receiving the name of oral lichen planus (OLP). Its frequency varies from 0,1 to 4% of the general population, with a higher incidence in women, around the 4th and 5th decades of life. Although the pathogenesis of OLP is related to a immune-cellular response, mainly mediated by T lymphocytes, its cause remains unknown. Considering its chronic nature, control of OLP aims to reduce symptoms and improve function, and agents with anti-inflammatory action, especially topical corticosteroids result in some degree of success in most patients, depending on the clinical presentation. However, some cases are resistant to the use of corticosteroids, thus justifying the search for new therapeutic options. The immunomodulation proved to be one of the main functions of probiotic bacteria, and recent studies have shown effect of probiotics on decreasing the expression of inflammatory markers, which enables the study of this therapy as an alternative to the control of OLP. Thus, this project aims to evaluate the effects of therapy with Bifidobacterium animalis subsp. lactis HN019 comparing with clobetasol propionate 0.05% in symptomatic patients with OLP referred for diagnosis and treatment of School of Dentistry of Ribeirão Preto - University of São Paulo (USP). The impact of the topical therapy (probiotic or corticosteroid) on the clinical, histopathological and immunopathological features will be evaluated. This project was previously submitted and approved by the Institutional Review Board of the School of Dentistry of Ribeirão Preto/USP, and all patients must give informed consent to participate in this study.

Detailed Description

This is a randomized double-blind clinical trial with symptomatic patients presenting OLP, which will be randomly assigned to either topical Bifidobacterium animalis subsp lactis HN019 or clobetasol propionate 0.05%. The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 (experimental group) or 0.05% clobetasol propionate (control group) for mouth washing, twice a day for 4 weeks. Patients will be instructed to maintain normal brushing and not to use or consume another corticosteroid and /or probiotic during the study. Outcomes measures will be symptoms (VAS and Likert-like scale), quality of life (SF-36 form), and clinical changes (erythema, reticulation, erosion/ulcer based on clinical photographs), which will be performed at baseline, 15 days (only VAS, Likert-like scale and photographs) and and at one month of treatment. All patients will undergo biopsies for the diagnosis of OLP, and those who consent will be submitted to an optional biopsy at the end of the topical treatment for histopathological and immunopathological characterization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Oral Lichen Planus

Keywords

Oral lichen planus, Probiotics, Immunomodulation.

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Model Description

Symptomatic patients presenting OLP will be randomly assigned to either topical Bifidobacterium animalis subsp lactis HN019 or clobetasol propionate 0.05%, and they will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 (experimental group) or 0.05% clobetasol propionate (control group) for mouth washing, twice a day for 4 weeks.

Masking

ParticipantInvestigator

Masking Description

Both patients and investigators who will assess the outcomes have no knowledge of the interventions assigned to individual participants.

Allocation

Randomized

Enrollment

22 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Bifidobacterium animalis subsp. lactis

Arm Type

Experimental

Arm Description

Intervention: Bifidobacterium animalis subsp. lactis HN019

Arm Title

Clobetasol propionate 0.05%

Arm Type

Active Comparator

Arm Description

Intervention: Clobetasol propionate 0.05%

Intervention Type

Drug

Intervention Name(s)

Bifidobacterium animalis subsp. lactis HN019

Other Intervention Name(s)

Probiotic

Intervention Description

The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.

Intervention Type

Drug

Intervention Name(s)

Clobetasol propionate 0.05%

Other Intervention Name(s)

Topical corticosteroid

Intervention Description

The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.

Primary Outcome Measure Information:

Title

Change in symptoms intensity measure

Description

Time Frame

4 weeks

Secondary Outcome Measure Information:

Title

Histopathological analysis

Description

Time Frame

Before (baseline) and one month after intensive topical therapy

Title

Immunohistochemical analysis

Description

Time Frame

After 4 weeks of intensive therapy.

Title

Venous blood collection

Description

10 ml of venous blood to evaluate the probiotic systemic effect, by means of the research of pro-inflammatory, anti-inflammatory and regulatory cytokines.

Time Frame

Before (baseline) and after 4 weeks of topical therapy

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Clinical inclusion Adults ≥ 18 years old, both genres, who consent to participate of the study; Presence of symptomatic reticular lesion and/or white-gray papules. In afro-descendent individuals, reticular lesions may be associated with hyperpigmented lesions; Additional clinical features such as ulcerative, erythematous, plaque and bullous lesions will be accepted in the presence of bilateral and symmetrical reticular lesions. Histopathological inclusion criteria Presence of subepithelial infiltrate predominantly lymphocytic, in band and confined to the subepithelial area. Liquefaction degeneration of the basal cells layer. Exclusion Criteria: Clinical exclusion criteria Exclusion of contact lichenoid lesions: the pattern of reticular lesion and / or papules should not be present only in areas of physical contact with restorative materials; Exclusion of lichenoid reaction to the drug: difficult to differentiate from OLP, however it is necessary to report all drugs in use by the patient; the comparison between patients on medication, and those who do not use medication is important to establish subgroups of OLP; Exclusion of chronic graft versus host disease (GVHD): differentiation between OLP and GVHD is established in most cases by medical history; Exclusion of immunocompromised patients or patients with systemic diseases of high complexity. Exclusion of patients who have previously used probiotic bacteria in the last 4 weeks prior to the study. Histopathological criteria for exclusion • Presence of epithelial dysplasia, absence of the lymphocytic inflammatory infiltrate band and liquefaction degeneration.

Overall Study Officials: